GnRH Antagonists in Uterine Fibroid Management
Introduction to GnRH Antagonists
- The American College of Radiology recommends GnRH antagonists (elagolix, linzagolix, relugolix) as FDA-approved second-line agents for fibroid-related heavy menstrual bleeding, to be used with add-back hormonal therapy to mitigate hypoestrogenic side effects while maintaining efficacy 1
Primary Clinical Roles
- GnRH antagonists effectively reduce heavy menstrual bleeding associated with fibroids and are positioned as second-line therapy after NSAIDs, oral contraceptives, and tranexamic acid fail 1
- GnRH antagonists achieve significant fibroid volume reduction comparable to GnRH agonists (18-50% reduction over 3-4 months) 1, 2
Mandatory Add-Back Therapy
- Combination treatment with low-dose estrogen and progestin is essential and FDA-approved for long-term management to prevent severe hypoestrogenic complications 1, 3
- Hypoestrogenic effects are substantially mitigated while maintaining therapeutic efficacy for bleeding control with add-back therapy 1, 3
Critical Clinical Pitfalls
- Cessation of GnRH antagonist therapy leads to rapid recurrence of symptoms, making these agents unsuitable as definitive long-term solutions without add-back therapy 3
- Fertility is actively suppressed during treatment, though these medications are often chosen by patients interested in uterus-preserving therapy or future fertility preservation 1, 3
Positioning Relative to Other Treatments
- When fibroid volume reduction is required in addition to bleeding control, GnRH antagonists are preferred 1, 2
- For preoperative preparation to reduce surgical complexity and blood loss, GnRH antagonists are preferred 1, 4
Preoperative Protocol
- Administer GnRH antagonists for 3-4 months to achieve maximal fibroid volume reduction before myomectomy or hysterectomy 4
- Schedule surgery promptly after completing the course, as fibroids rapidly return to pretreatment size 4